Patient Engagement and Patient Centricity Series Part II: Types of Patient Advocates Blog Patient Engagement and Patient Centricity Series Part II: Types of Patient Advocates Nirpal Virdee, Synchrogenix’s Global Head of Transparency and Disclosure recently sat down with Trishna Bharadia,…CertaraNovember 11, 2019
ICER’s Unsupported Drug Price Increase Report: An Analysis Blog ICER’s Unsupported Drug Price Increase Report: An Analysis We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…CertaraOctober 24, 2019
Health Canada PRCI Guiding Principles and Observations Blog Health Canada PRCI Guiding Principles and Observations Health Canada released guidance on March 12, 2019 pertaining to its Public Release of Clinical…CertaraSeptember 16, 2019
Common Questions about Define-XML and the Stylesheet Blog Common Questions about Define-XML and the Stylesheet In this blog, we answer common questions about Define-XML and the Stylesheet, including all you…CertaraAugust 22, 2019
Trends for Market Access, HEOR, and Real World Evidence Blog Trends for Market Access, HEOR, and Real World Evidence This blog reviews trends for using health economics and outcomes research and real-world evidence to…CertaraMay 10, 2019
Real World Evidence Marches Forward in Drug Development Blog Real World Evidence Marches Forward in Drug Development The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…CertaraMarch 20, 2019
Managing Immunogenicity Using Quantitative Systems Pharmacology Blog Managing Immunogenicity Using Quantitative Systems Pharmacology The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving…CertaraFebruary 22, 2019
7 Things to Know About the China Pharmaceutical Industry Blog 7 Things to Know About the China Pharmaceutical Industry China is the second largest pharmaceutical market in the world. Demand is likely to increase…CertaraOctober 16, 2018
FDA’s New ANDA Submissions Guidance: Key Points Blog FDA’s New ANDA Submissions Guidance: Key Points The U.S. Food and Drug Administration (FDA) published notice of a new ANDA submissions guidance…CertaraSeptember 27, 2018
Clinical Pharmacology Gap Analysis: Lessons Learned Blog Clinical Pharmacology Gap Analysis: Lessons Learned Clinical pharmacology gap analysis is a tool for outlining your drug program’s needs, prioritizing these…CertaraAugust 10, 2018